ARTICLE | Clinical News
Enzo completes Phase I EHT899 trial
March 28, 2000 8:00 AM UTC
ENZ said its EHT899 oral hepatitis B virus (HBV) antigens showed no significant side effects and had improvement in disease symptoms in a 15-patient Israeli trial to treat chronic HBV infection. ...